One systematic review provided an estimated pooled incidence rate for CIDP of 0.33 per 100,000 person-years, and an estimated pooled prevalence rate of 2.81 per 100,000 people. There is substantial heterogeneity in incidence and prevalence across individual studies, due in part to use of different diagnostic criteria and underrecognition of CIDP variants.[2]Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019 Aug;18(8):784-94.
http://www.ncbi.nlm.nih.gov/pubmed/31076244?tool=bestpractice.com
[15]Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3-4):161-72.
https://karger.com/ned/article/52/3-4/161/226983/Incidence-and-Prevalence-of-Chronic-Inflammatory
http://www.ncbi.nlm.nih.gov/pubmed/30669140?tool=bestpractice.com
[16]Broers MC, Bunschoten C, Drenthen J, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021 Jun;28(6):2065-73.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14796
http://www.ncbi.nlm.nih.gov/pubmed/33657260?tool=bestpractice.com
CIDP can occur at any age, with most common age of onset being between 40 and 60 years.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
CIDP is more common in men, with reported male-to-female ratios of between 1.4 and 4.4.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[2]Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019 Aug;18(8):784-94.
http://www.ncbi.nlm.nih.gov/pubmed/31076244?tool=bestpractice.com
[15]Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3-4):161-72.
https://karger.com/ned/article/52/3-4/161/226983/Incidence-and-Prevalence-of-Chronic-Inflammatory
http://www.ncbi.nlm.nih.gov/pubmed/30669140?tool=bestpractice.com
There are no known differences between ethnic groups or geographic regions.